Canada Markets close in 4 hrs 40 mins

PFE Jan 2024 50.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
6.200.00 (0.00%)
As of 02:31PM EDT. Market open.
Full screen
Loading interactive chart...
  • Bloomberg

    Covid Vaccine Maker Novavax Tumbles After Cutting Annual Sales Forecast 50%

    (Bloomberg) -- Novavax Inc. shares had their biggest loss in more than three years as the drugmaker slashed its 2022 revenue forecast late Monday on disappointing demand for its Covid-19 vaccine that trailed competitors getting to market.Most Read from BloombergTrump Under Intense Legal Scrutiny After FBI Searches Mar-a-LagoChina Seizes on Pelosi Visit to Set ‘New Normal’ for TaiwanSan Francisco ‘Froth is Gone’ as Wealth Fades, Housing SlumpsWhy Carlyle's Billionaire Founders Had Enough of Their

  • Reuters

    UPDATE 1-EU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot

    The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday. The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID - the original strain first identified in China, and the Omicron offshoots BA.4/5 that are currently behind most cases in Europe. A rolling review means the EMA assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.

  • Business Wire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.